Bispecific Aptamer Targeting CD44 and EpCAM for Ovarian Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ovarian cancer, particularly advanced stages, face challenges with chemoresistance and peritoneal metastasis, and existing bispecific antibodies are difficult to produce and exhibit high immunogenicity.
Innovation Solution
Development of bispecific aptamers that specifically bind to CD44 and EpCAM, fusion of single CD44 and EpCAM aptamers into a unit with a 23 bp adaptor and 2-3 unpaired base linkers, enhancing circulation half-life and reducing renal filtration, allowing efficient targeting and internalization in ovarian cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-based bispecific molecules are used to target two different molecules, then therapeutic efficacy is improved and drug resistance is reduced, but immunogenicity increases and production becomes difficult
Solution Approach 1:
The patent uses aptamers (nucleic acid molecules) as copies or alternatives to antibodies. Aptamers bind to the same targets as antibodies but are synthesized chemically rather than biologically, eliminating immunogenicity issues while maintaining therapeutic efficacy. The aptamer-based bispecific molecules replicate the dual-targeting capability of antibody bispecifics without the harmful immunogenic effects.
Solution Approach 2:
The patent replaces the biological production system (cellular immune system) with a chemical synthesis system. Instead of using hybridoma technology or genetic engineering to produce antibodies, the aptamers are synthesized through chemical methods, simplifying production and eliminating immunogenicity while maintaining binding specificity and therapeutic effect.
2Reliability
If antibody-based bispecific molecules are used to target two different molecules, then therapeutic efficacy is improved, but production becomes difficult due to complicated technologies
Solution Approach 1:
The patent replaces complex biological production systems (hybrid-hybridoma and genetic engineering) with chemical synthesis methods. Aptamers can be produced through standardized chemical oligonucleotide synthesis, eliminating the need for cell fusion, cloning, and complex protein expression systems, thereby significantly simplifying manufacturing while maintaining therapeutic efficacy.
Solution Approach 2:
The patent creates simplified copies of the complex antibody production process by using chemically synthesized aptamers. These aptamer copies can be produced through straightforward chemical reactions without requiring biological systems, reducing production complexity and enabling more scalable manufacturing of bisspecific therapeutic molecules.
3Object-affected harmful factors
If single aptamers are used to target tumor markers, then non-immunogenicity and cell-free synthesis are achieved, but therapeutic effect against tumorigenesis is insufficient
Solution Approach 1:
The patent merges multiple single aptamers into a single bispecific aptamer molecule that can simultaneously bind to two different tumor markers (CD44 and EpCAM). This combination approach maintains the non-immunogenicity advantage of aptamers while achieving enhanced therapeutic effect through dual-targeting, overcoming the limitations of single aptamer therapy.
Solution Approach 2:
The patent creates a multi-functional bispecific aptamer that performs multiple functions: binding to CD44, binding to EpCAM, and inducing tumor cell death. This single molecule integrates the advantages of multiple single aptamers, providing both non-immunogenicity and enhanced therapeutic efficacy through its ability to target multiple tumor markers simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bispecific CD44−EpCAM aptamer significantly inhibits ovarian cancer cell growth, suppresses intraperitoneal tumor progression, and induces apoptosis in ovarian cancer cells, demonstrating improved efficacy over single aptamers and reduced toxicity.
Implementation Method 1
Bispecific aptamers having a first end that specifically binds to a first tumor specific marker, tumor antigen, or viral protein and a second end that specifically binds to a second tumor specific marker, tumor antigen, or viral protein
Implementation Method 2
A single EpCAM aptamer consisting of 19-nt RNA possesses similar binding affinity as antibodies and is efficiently internalized through receptor-mediated endocytosis
Data Source
AI summary
Bispecific aptamers having a first end that specifically binds to a first tumor specific marker, tumor antigen, or viral protein and a second end that specifically binds to a second tumor specific marker, tumor antigen, or viral protein are provide. The bispecific aptamers can be used to treat cancer or virally infected cells. Generally, the bispecific aptamers bind to two surface proteins, preferably different proteins, on the same cell. In a preferred embodiment the bispecific aptamers bind to two different tumor markers, tumor antigens, tumor specific proteins and combinations thereof.